Home » Stocks » PAVM

PAVmed Inc. (PAVM)

Stock Price: $2.01 USD -0.06 (-2.90%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $2.03 +0.02 (1.00%) Jan 15, 7:57 PM
Market Cap 144.53M
Revenue (ttm) n/a
Net Income (ttm) -32.06M
Shares Out 48.38M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.01
Previous Close $2.07
Change ($) -0.06
Change (%) -2.90%
Day's Open 2.06
Day's Range 1.96 - 2.15
Day's Volume 2,165,636
52-Week Range 1.37 - 3.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...

GlobeNewsWire - 1 week ago

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...

GlobeNewsWire - 3 weeks ago

NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...

GlobeNewsWire - 4 weeks ago

NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...

Seeking Alpha - 1 month ago

PAVmed's (PAVM) CEO Lishan Aklog on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 1 month ago

Conference call to be held today at 4:30 p.m. Eastern time

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, toda...

Seeking Alpha - 2 months ago

The company has multiple promising medical devices in various states of regulatory approval, although three of these have already entered the commercial stage. Yet, like for most pre-revenue m...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, t...

Seeking Alpha - 4 months ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2020 Results and Business Update - Earnings Call Transcript

GlobeNewsWire - 4 months ago

Conference call to be held today at 4:30 p.m. Eastern time

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, to...

GlobeNewsWire - 5 months ago

NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, to...

GlobeNewsWire - 6 months ago

NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, to...

GlobeNewsWire - 7 months ago

NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the C...

GlobeNewsWire - 7 months ago

NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...

GlobeNewsWire - 7 months ago

NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...

GlobeNewsWire - 7 months ago

Executed LOI with Canon Virginia, Inc. to develop and implement commercial grade processes to manufacture molded resorbable pediatric ear tubes from aqueous silk fibroin

Seeking Alpha - 7 months ago

PAVMed Is About To Enter The Commercialization Phase

Seeking Alpha - 7 months ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2020 Results and Business Update - Earnings Call Transcript

GlobeNewsWire - 7 months ago

Conference call to be held today at 4:30 p.m. Eastern time

Seeking Alpha - 8 months ago

PAVmed: Small Medical Device Maker With New FDA Approval And Multiple Catalysts

GlobeNewsWire - 8 months ago

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it h...

Seeking Alpha - 9 months ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Conference call to be held today at 4:30 p.m. Eastern time

GlobeNewsWire - 9 months ago

NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that...

GlobeNewsWire - 9 months ago

NEW YORK, March 31, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it h...

GlobeNewsWire - 10 months ago

Incorporates data from successful clinical safety study in which all patients met pre-specified safety and effectiveness endpoints

GlobeNewsWire - 10 months ago

Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires mult...

GlobeNewsWire - 10 months ago

Lucid secures exclusive option to license biomarker technology to detect progression from nondysplastic to dysplastic BE using EsoCheck to allow curative ablation before deadly esophageal canc...

GlobeNewsWire - 10 months ago

Disposable single-use device designed to provide safer, more efficient and cost-effective ablation of dysplastic Barrett’s Esophagus, complementing Lucid Diagnostics’ EsoGuard™ and EsoCheck™ p...

GlobeNewsWire - 11 months ago

NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...

GlobeNewsWire - 1 year ago

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it ha...

GlobeNewsWire - 1 year ago

First commercially available DNA test designed to facilitate the diagnosis of Barrett’s Esophagus and related precursors to highly lethal form of esophageal cancer

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an upd...

Seeking Alpha - 1 year ago

PAVmed Has Multiple Paths To Growth

Seeking Alpha - 1 year ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Conference call to be held on November 21, 2019 at 4:30 p.m. Eastern time

GlobeNewsWire - 1 year ago

Secures exclusive worldwide license for Nondispersive Infrared (NDIR) laser technology

GlobeNewsWire - 1 year ago

Unprecedented six-month maintenance-free implant duration achieved

Seeking Alpha - 1 year ago

PAVM has a market cap of $35 million with one FDA approved device and another expected by early 2020. The TAM for these devices is $3B+ in the U.S. alone.

Seeking Alpha - 1 year ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time

GlobeNewsWire - 1 year ago

NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that ...

Seeking Alpha - 1 year ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q4 2018 Results and Business Update- Earnings Call Transcript

About PAVM

PAVmed operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; EsoCheck, an non-invasive cell collection device and DNA biomarkers to detect esophageal cancer precursor; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation devi... [Read more...]

Industry
Medical Devices
IPO Date
Apr 28, 2016
CEO
Dr. Lishan Aklog M.D.
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
PAVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PAVmed stock is "Strong Buy." The 12-month stock price forecast is 5.08, which is an increase of 152.74% from the latest price.

Price Target
$5.08
(152.74% upside)
Analyst Consensus: Strong Buy